Trantinterol, a novel β2-adrenoceptor agonist, noncompetitively inhibits p-glycoprotein function in vitro and in vivo

Molecular Pharmaceutics

Volumn 12, Issue 1, 2015, Pages 1-9

  Wang, Tingting ^a,b   Sun, Yantong ^a   Ma, Wenxiao ^a,c   Yang, Zhichao ^a   Yang, Junfeng ^a   Liu, Jingrui ^a   Fan, Hongbo ^a   Yang, Yan ^a   Gu, Jingkai ^a,b   Fawcett, John Paul ^d   Guo, Yingjie ^a  

^a JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c Jiangsu Hengrui Medicine Co Ltd   (China)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Caco 2 cells; MDCK MDR1 cells; noncompetitive inhibitor; P gp; trantinterol

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLENBUTEROL; CYCLOSPORIN A; CYCLOSPORIN D; DIAZEPAM; DIGOXIN; DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROTEIN INHIBITOR; RHODAMINE 123; TRANTINTEROL; UNCLASSIFIED DRUG; VERAPAMIL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLOSPORIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONFORMATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PURITY; DRUG STRUCTURE; DRUG UPTAKE; ELIMINATION RATE CONSTANT; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MALE; MAXIMUM PLASMA CONCENTRATION; MDCK CELL LINE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN FUNCTION; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DOG; DRUG SCREENING; HUMAN; TRANSPORT AT THE CELLULAR LEVEL; WISTAR RAT;

ADENOSINE TRIPHOSPHATASES; ADRENERGIC BETA-AGONISTS; ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BINDING SITES; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CLENBUTEROL; CYCLOSPORINE; DIGOXIN; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MALE; P-GLYCOPROTEIN; PACLITAXEL; RATS; RATS, WISTAR; RHODAMINE 123;

EID: 84920263128     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500239v     Document Type: Article

References (25)

1. Choi, Y. H.; Yu, A. M. ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development Curr. Pharm. Des. 2014, 20, 793-807
2. Konig, J.; Muller, F.; Fromm, M. F. Transporters and drug-drug interactions: important determinants of drug disposition and effects Pharmacol. Rev. 2013, 65, 944-966
3. Cheung, Y. T.; Yap, K. Y.; Chui, W. K.; Chan, A. Drug-drug interactions between oral antiepileptics and oral anticancer drugs: implications to clinicians Eur. Neurol. 2010, 64, 88-94
4. Hamidi, M. Role of P-glycoprotein in tissue uptake of indinavir in rat Life Sci. 2006, 79, 991-998
5. Marchetti, S.; Mazzanti, R.; Beijnen, J. H.; Schellens, J. H. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein) Oncologist 2007, 12, 927-941
6. Yang, J.; Guan, J.; Pan, L.; Jiang, K.; Cheng, M.; Li, F. Enantioseparation and impurity determination of the enantiomers of novel phenylethanolamine derivatives by high performance liquid chromatography on amylose stationary phase Anal. Chim. Acta 2008, 610, 263-267
7. Gan, L. L.; Wang, M. W.; Cheng, M. S.; Pan, L. Trachea relaxing effects and beta2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits Biol. Pharm. Bull. 2003, 26, 323-328
8. Hao, Z.; Zhang, Y.; Pan, L.; Su, X.; Cheng, M.; Wang, M.; Zhao, H.; Wu, Y. Comparison of enantiomers of SPFF, a novel beta2-Adrenoceptor agonist, in bronchodilating effect in guinea pigs Biol. Pharm. Bull. 2008, 31, 866-872
9. Li, K.; Qin, F.; Jing, L.; Li, F.; Guo, X. In vivo and in vitro metabolism of a novel beta2-adrenoceptor agonist, trantinterol: metabolites isolation and identification by LC-MS/MS and NMR Anal. Bioanal. Chem. 2013, 405, 2619-2634
10. Wang, Y.; Lu, X.; Jiang, K.; Xiong, Z.; Cheng, M.; Li, F. Liquid chromatography-mass spectrometry for analysis of a novel beta(2)-adrenoceptor agonist trantinterol and its metabolites in beagle dog urine Biomed. Chromatogr. 2010, 24, 274-280
11. Jiang, K.; Li, K.; Qin, F.; Lu, X.; Li, F. Assessment of a novel beta2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities Toxicol In Vitro 2011, 25, 1033-1038
12. Valenzuela, B.; Nacher, A.; Casabo, V. G.; Martin-Villodre, A. The influence of active secretion processes on intestinal absorption of salbutamol in the rat Eur. J. Pharm. Biopharm. 2001, 52, 31-37
13. Valenzuela, B.; Nacher, A.; Ruiz-Carretero, P.; Martin-Villodre, A.; Lopez-Carballo, G.; Barettino, D. Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process J. Pharm. Sci. 2004, 93, 1641-1648
14. Chang, C.; Bahadduri, P. M.; Polli, J. E.; Swaan, P. W.; Ekins, S. Rapid identification of P-glycoprotein substrates and inhibitors Drug Metab. Dispos. 2006, 34, 1976-1984
15. US FDA. US Departmentof Health and Human Services, FDA, Center for Drug Evaluation andResearch, Rockville, MD, USA, (2001; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf.
16. Rapposelli, S.; Coi, A.; Imbriani, M.; Bianucci, A. M. Development of classification models for identifying ?true? P-glycoprotein (P-gp) inhibitors through inhibition, ATPase activation and monolayer efflux assays Int. J. Mol. Sci. 2012, 13, 6924-6943
17. Shirasaka, Y.; Onishi, Y.; Sakurai, A.; Nakagawa, H.; Ishikawa, T.; Yamashita, S. Evaluation of human P-glycoprotein (MDR1/ABCB1) ATPase activity assay method by comparing with in vitro transport measurements: Michaelis-Menten kinetic analysis to estimate the affinity of P-glycoprotein to drugs Biol. Pharm. Bull. 2006, 29, 2465-2471
18. Oliveinstein, R.; Al Jahdali, H.; Alkhamis, N.; Halwani, R.; Al-Muhsen, S.; Hamid, Q. Challeges in the management of severe asthma: role of current and future therapies Curr. Pharm. Des. 2011, 17, 703-711
19. Valenzuela, B.; Lopez-Pintor, E.; Perez-Ruixo, J. J.; Nacher, A.; Martin-Villodre, A.; Casabo, V. G. Modelling intestinal absorption of salbutamol sulphate in rats Int. J. Pharm. 2006, 314, 21-30
20. Goda, K.; Fenyvesi, F.; Bacso, Z.; Nagy, H.; Marian, T.; Megyeri, A.; Krasznai, Z.; Juhasz, I.; Vecsernyes, M.; Szabo, G., Jr. Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody J. Pharmacol. Exp. Ther. 2007, 320, 81-88
21. Maki, N.; Moitra, K.; Ghosh, P.; Dey, S. Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein J. Biol. Chem. 2006, 281, 10769-10777
22. Urbatsch, I. L.; Sankaran, B.; Weber, J.; Senior, A. E. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site J. Biol. Chem. 1995, 270, 19383-19390
23. Varma, M. V. S.; Ashokraj, Y.; Dey, C. S.; Panchagnula, R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement Pharmacol. Res. 2003, 48, 347-359
24. Taipalensuu, J.; Tavelin, S.; Lazorava, L.; Svensson, A. C.; Artursson, P. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin a marker of MDR1-dependent drug efflux activity Eur. J. Pharm. Sci. 2004, 21, 69-75
25. Sun, Y. T.; Gao, F.; Zhang, M. L.; Cui, X. Y.; Wang, Z. H.; Gu, J. K. Effect of trantinterol on cytochrome P450 enzymes J. Jilin Univ., Sci. Ed. 2010, 48, 1061-1064